Revance Therapeutics, INC Form 4 insider transactions

Revance Therapeutics CFO Tobin Schilke reports the withholding of shares to cover tax obligations and the sale of shares to cover tax withholding obligations related to vesting restricted stock awards and performance-based restricted stock units.

Mark Foley, CEO of Revance Therapeutics, reports the withholding of shares to cover tax obligations related to vesting restricted stock awards and performance-based restricted stock units.

Revance Therapeutics CEO Mark Foley recently purchased 30,000 shares of the company's common stock at $6.98 per share, increasing his direct holdings.

Dustin Sjuts, President of Revance Therapeutics, reports the vesting of performance-based restricted stock units (PSUs) on February 29, 2024.

Dwight Moxie, CLO & GC of Revance Therapeutics, reports the vesting of performance-based restricted stock units (PSUs) on February 29, 2024.

CFO of Revance Therapeutics, Tobin Schilke, reports the vesting of performance-based restricted stock units (PSUs) on February 29, 2024, resulting in the acquisition of 17,447 shares of common stock.

Revance Therapeutics CEO Mark Foley reports the vesting of performance-based restricted stock units (PSUs) and adjustments to his beneficial ownership.